Now prescribing BPC-157, TB-500, Semax, MOTS-c and Epitalon

PepScribe

Guide · 8 min read

Compounding & the law. | Reddit

Last updated October 4, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

Pharmacy compounding is older than the modern FDA, and it’s governed by a specific federal framework that matters a lot for peptide therapy. Here’s how it actually works.

What compounding is.

Compounding is the practice of a licensed pharmacist preparing a customized medication for a specific patient based on a specific prescription. It predates industrial drug manufacturing, before mass-produced brand-name drugs existed, nearly all medications were compounded.

Today, compounding fills gaps that commercial pharmaceuticals can’t: patient-specific dose strengths, combination formulations, preservative-free preparations for allergic patients, liquid versions of drugs only commercially available as tablets, and so on. It’s a legal, regulated pharmacy practice that has existed for as long as modern pharmacy has.

Critically: compounded medications are not FDA-approved drugs. That’s a regulatory distinction, not a quality statement. Compounded preparations are legally prepared by licensed pharmacies and are subject to pharmacy quality standards, but they don’t go through the multi-year FDA approval process that brand-name drugs do.

503A and 503B

The two frameworks.

The 2013 Drug Quality and Security Act created the modern structure. It split compounding pharmacies into two categories with different rules.

Compounding pathways

503A vs 503B pathways

Same four stages, two different answers at every one. The upper track is compounded against a named prescription; the lower is batched for a clinic's shelf.

503A · patient-specific

What PepScribe uses

PT

Patient

a named individual

RX

Clinician Rx

written for one person

503A

503A pharmacy

compounds to order

PT

Patient receives

direct to the door

503B · office and clinic stock

FAC

Outsourcing facility

registered 503B

LOT

Batch compound

no patient named

CLINIC

Clinic stock

held on a shelf

CLIN

Clinician administers

in the office

503A and 503B compounding pathways, by stage
Stage503A, patient-specific503B, office and clinic stock
OriginPatient, a named individualOutsourcing facility, registered 503B
What is madeClinician Rx, written for one personBatch compound, no patient named
Custody503A pharmacy, compounds to orderClinic stock, held on a shelf
DeliveryPatient receives, direct to the doorClinician administers, in the office
Both pathways are legal and FDA-regulated. PepScribe uses the patient-specific 503A pathway, so every dose is compounded against a named prescription rather than drawn from batched clinic stock.

Section 503A

Traditional compounding

Licensed pharmacies or physician offices preparing patient-specific prescriptions. Each preparation requires an active, named prescription. Regulated primarily by state boards of pharmacy, with FDA oversight on bulk drug substances. Most compounded semaglutide, tirzepatide, and NAD+ prescribed via telehealth comes from 503A pharmacies, including everything PepScribe ships.

Section 503B

Outsourcing facilities

Larger-scale compounding facilities registered directly with the FDA. Subject to Current Good Manufacturing Practice (cGMP) requirements similar to commercial pharmaceutical manufacturing. Can prepare compounded drugs for office use without patient-specific prescriptions. 503B looks more like a pharmaceutical manufacturer than a traditional pharmacy, higher throughput, more rigorous quality controls, direct FDA oversight.

Brand-name vs. compounded.

A brand-name drug (Ozempic, Wegovy, Mounjaro, Zepbound) is a specific formulation that the manufacturer submitted to the FDA for approval. The FDA reviewed safety, efficacy, manufacturing, and labeling; once approved, the drug can be marketed for specific indications and manufactured at commercial scale.

A compounded version is based on the same underlying molecule (for example, semaglutide) but is prepared by a pharmacy under the 503A or 503B framework rather than by the brand manufacturer. The compounded version is not FDA-approved, is not legally marketed as a commercial product, and is prepared in response to specific prescriptions.

Both can be effective. They’re regulated differently, priced differently, and come with different risk profiles around quality control. That’s the honest answer about what the distinction is and isn’t.

FDA bulk drug substances

The three categories FDA uses for bulk drug substances.

The FDA sorts bulk drug substances nominated for 503A compounding into three categories. No category is an FDA approval.

Category 1

Under evaluation

Bulk drug substances FDA is evaluating for the 503A Bulks List. Under its interim policy, FDA does not intend to take action against a 503A pharmacy that compounds with a Category 1 substance when the policy's conditions are met.

Category 2

Significant safety concerns

Bulk drug substances FDA has identified as raising significant safety concerns. BPC-157, TB-500 and Semax were listed here until April 2026, and Thymosin Alpha-1 until September 2024; FDA removed them because the nominations were withdrawn. Selank was removed in September 2024 because the nominator intended a different substance. None is FDA-approved or on the 503A Bulks List.

Category 3

Nominated without adequate support

Bulk drug substances nominated for the 503A Bulks List without enough supporting information for FDA to evaluate them.

Drug shortages change the picture.

The FDA maintains a public list of drugs officially in shortage. When a brand-name drug is on that list, the regulatory picture for compounding shifts meaningfully: compounding pharmacies gain explicit permission to prepare patient-specific versions of the shortage drug at scale.

This is the regulatory mechanism that has allowed compounding pharmacies to serve millions of patients who couldn’t access brand-name Ozempic or Wegovy during sustained manufacturer shortages. It’s not a loophole, it’s the exact use case Congress designed 503A to address.

Shortage status is dynamic. When the FDA declares a drug resolved and removes it from the shortage list, compounding pharmacies lose the explicit permission and have to wind down production of that specific compound. This has been a source of uncertainty for GLP-1 compounding specifically; your clinician and pharmacy monitor shortage-list status closely.

Recent regulatory history.

The last few years have seen unusually active regulation of peptide compounding.

September 29, 2023: FDA added BPC-157 to Category 2, alongside several other research peptides. Gray-market vendors kept selling “research chemical” versions, which are unregulated and fall outside the pharmacy compounding framework entirely.

April 2026: FDA removed twelve peptides, including BPC-157, TB-500 and Semax, from Category 2 because the nominations were withdrawn. None of them moved to Category 1 or onto the 503A Bulks List.

July 23 to 24, 2026: FDA’s Pharmacy Compounding Advisory Committee recommended adding six of those peptides (BPC-157, KPV, TB-500, MOTs-C, Semax and Epitalon) to the 503A Bulks List and voted against a seventh. The votes are advisory, and FDA has not yet acted on them.

The PepScribe Peptide Library tracks each of these peptides’ regulatory status on its research page.

What this means for patients.

If you’re considering peptide therapy through PepScribe or any other provider, a few things are worth understanding.

Compounded is not equivalent to unregulated. Licensed 503A and 503B compounding is a federally regulated pharmacy practice. That’s different from the purely black-market “research chemical” ecosystem, which is not regulated at all and where product identity and purity can’t be verified.

Regulatory status can change. A peptide’s legal compoundability is a snapshot of current FDA policy. FDA can move a substance between its category lists or add it to the 503A Bulks List, and shortage-list entries can come and go. PepScribe offers only treatments that licensed clinicians prescribe and licensed 503A pharmacies compound.

Research pages are education. Our consultation-first research pages cover compounds like BPC-157 and TB-500 because the research is interesting and patient-relevant. Whether any of them fits you is a decision for a clinician, made in a consultation.

Keep reading

More guides

Ready to see what fits you?

A 3-minute assessment lets a licensed clinician review your goals and recommend what’s legally available today.